CMS (00867) has announced that its subsidiary Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on November 3, 2026, for the New Drug Application (NDA) of ruxolitinib phosphate cream (the "Product" or "Lumirix®") for the treatment of vitiligo.

The product is indicated for the treatment of non-segmental vitiligo with facial involvement in adolescent and adult patients aged 12 years and above. It is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo, addressing a long-standing unmet clinical need.

This approval fills a gap in the vitiligo treatment landscape in Singapore. In addition to Singapore, Rxilient Medical has already launched sales of Lumirix® (vitiligo indication) in the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and the Taiwan region.

CMS has been pursuing its "industry internationalization" strategy since 2022, using Singapore as a hub for its emerging market business to build an efficient value loop with full-chain coordination across research, production, and sales. Rxilient Medical is the group's commercialization subsidiary for expanding into emerging markets. With "global localization" as its core strategy, it is committed to bringing global innovative therapies to emerging markets through full-chain commercialization capabilities covering drug introduction, development and registration, and marketing promotion, benefiting local patients.